These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 25140852)
21. Two-once-daily fixed-dose NRTI combinations for HIV. Med Lett Drugs Ther; 2005 Feb; 47(1203):19-20. PubMed ID: 15767973 [TBL] [Abstract][Full Text] [Related]
22. FDA PrEPares to reduce risk of HIV infection with Truvada®. Breeze S Expert Rev Clin Pharmacol; 2012 Sep; 5(5):499. PubMed ID: 23272332 [No Abstract] [Full Text] [Related]
23. FDA treads carefully with PrEP. Holmes D Lancet Infect Dis; 2012 Jul; 12(7):515-6. PubMed ID: 22930826 [No Abstract] [Full Text] [Related]
24. Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition. Miller V; Grant RM Clin Pharmacol Ther; 2014 Aug; 96(2):153-5. PubMed ID: 25056397 [TBL] [Abstract][Full Text] [Related]
26. More pre-exposure prophylaxis for rising HIV infection? Barreiro P AIDS Rev; 2014; 16(2):118-9. PubMed ID: 24984768 [No Abstract] [Full Text] [Related]
27. Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS; 2011 Jun; 25(6):383. PubMed ID: 21612547 [No Abstract] [Full Text] [Related]
28. Systemic preexposure prophylaxis for human immunodeficiency virus infection. Romanelli F; Murphy B Pharmacotherapy; 2010 Oct; 30(10):1021-30. PubMed ID: 20874040 [TBL] [Abstract][Full Text] [Related]
30. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. van de Vijver DA; Boucher CA Curr Opin Infect Dis; 2010 Dec; 23(6):621-7. PubMed ID: 20847692 [TBL] [Abstract][Full Text] [Related]
31. Treatment options for HIV, AIDS. FDA Consum; 2004; 38(6):4. PubMed ID: 15675011 [No Abstract] [Full Text] [Related]
33. First of a kind in HIV treatment. FDA Consum; 2006; 40(6):34. PubMed ID: 17333565 [TBL] [Abstract][Full Text] [Related]
34. The medicalization of HIV prevention: new opportunities beset by old challenges. Bayer R Milbank Q; 2014 Sep; 92(3):434-7. PubMed ID: 25199892 [No Abstract] [Full Text] [Related]
35. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Behrens G; Maserati R; Rieger A; Domingo P; Abel F; Wang H; Pearce G Antivir Ther; 2012; 17(6):1011-20. PubMed ID: 22910324 [TBL] [Abstract][Full Text] [Related]
36. Pre-exposure chemoprophylaxis of HIV infection: quo vadis? Clercq ED Biochem Pharmacol; 2012 Mar; 83(5):567-73. PubMed ID: 22067069 [TBL] [Abstract][Full Text] [Related]
37. Potential HIV prophylaxis enters Canadian pilot trial. Lawson J CMAJ; 2014 May; 186(8):E234. PubMed ID: 24710911 [No Abstract] [Full Text] [Related]
38. HIV prevention trial in women is abandoned after drugs show no impact on infection rates. Roehr B BMJ; 2011 Apr; 342():d2613. PubMed ID: 21508055 [No Abstract] [Full Text] [Related]
39. Ethical challenges of preexposure prophylaxis for HIV. Jay JS; Gostin LO JAMA; 2012 Sep; 308(9):867-8. PubMed ID: 22847147 [No Abstract] [Full Text] [Related]
40. Another blue pill for sex: Preventing HIV with Truvada PrEP--already at a pharmacy near you. Vázquez E Posit Aware; 2011; 23(5):25-7. PubMed ID: 22563594 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]